Menin/PRMT5/Hedgehog Signaling: A Potential Target for the Treatment of Multiple Endocrine Neoplasia Type 1 Tumors

10.1038/nrc1610

10.1126/science.276.5311.404

10.1002/humu.20605

10.1038/nature10806

10.1016/S0092-8674(00)80967-8

10.1073/pnas.0408836102

10.1073/pnas.0503484102

10.1016/j.ccr.2009.12.034

10.1128/MCB.24.21.9630-9645.2004

10.1158/0008-5472.CAN-12-3158

10.1016/j.devcel.2011.04.018

10.1101/gad.1546307

10.1016/j.devcel.2008.11.010

10.1038/34201

10.1200/JCO.2005.04.4974

10.4161/cbt.5.11.3458

10.1038/nm.2473

10.2337/db09-0914

10.1126/science.1171362

10.1128/MCB.23.17.6075-6085.2003

10.1056/NEJMoa0902903

10.1002/bjs.5280

10.1016/j.surg.2004.06.049

10.1056/NEJMoa1113713

A study of GDC-0449 (hedgehog pathway inhibitor) in patients treated with GDC-0449 in a previous Genentech-sponsored Phase I or II cancer study. http://clinicaltrials.gov/ct2/show/NCT00959647?term=NCT00959647&rank=1

GDC-0449 and erlotinib hydrochloride with or without gemcitabine hydrochloride in treating patients with metastatic pancreatic cancer or solid tumors that cannot be removed by surgery. http://clinicaltrials.gov/ct2/show/NCT00878163?term=NCT00878163&rank=1